Literature DB >> 16729161

[Health care to HIV/AIDS patients in Brazil].

Margareth Crisóstomo Portela1, Michel Lotrowska.   

Abstract

This study was intended to assess care provided to those living with HIV/AIDS in Brazil and the Brazilian Unified Health System (SUS) capacity of delivering interventions to cope with the epidemic as well as to discuss the sustainability of the Brazilian initiative of providing universal free access to antiretrovirals (ARVs). Original data from a study comprising 119 respondents on the potential capacity of delivering a prospective HIV vaccine in Brazil was used. Inpatient and pharmaceutical care was based on data from the SUS Hospital Information System and Drug Logistics Management Systems of the National Program for STD/AIDS. The study results indicate good performance of the Brazilian ARV Access Program but access to treatment of opportunistic infections was, however, unsatisfactory. The rates covered by SUS for AIDS hospital admissions remained very low, on average around R$700 in 2004. Health care to HIV/AIDS patients has been considered a citizen's right strongly supported by an effective joint action of the Brazilian government and civil society. The current challenges are fine monitoring of processes and program results and ensuring sustainability of universal free ARV access.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16729161     DOI: 10.1590/s0034-89102006000800010

Source DB:  PubMed          Journal:  Rev Saude Publica        ISSN: 0034-8910            Impact factor:   2.106


  1 in total

1.  The HIV-Brazil cohort study: design, methods and participant characteristics.

Authors:  Alexandre Grangeiro; Maria Mercedes Escuder; Alex Jones Flores Cassenote; Alex Jones Flores Cassanote; Rosa Alencar Souza; Artur O Kalichman; Valdiléa G Veloso; Valdiléa Veloso; Maria Letícia Rodrigues Ikeda; Nêmora Tregnago Barcellos; Carlos Brites; Unai Tupinanbás; Noaldo O Lucena; Carlos Lima da Silva; Heloisa Ramos Lacerda; Beatriz Grinsztejn; Euclides Ayres Castilho
Journal:  PLoS One       Date:  2014-05-01       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.